TC was reduced from ( 6.30 0.86 ) mmol/L at baseline to ( 5.92 0.75 ) mmol/L ( -6.03 % , P > 0.05 ) at week 3 and ( 5.43 0.77 ) mmol/L ( -13.8 % , P < 0.05 ) at week 6 in treatment group , from ( 6.20 0.76 ) mmol/L at week 0 to ( 5.70 0.76 ) mmol/L ( -8.06 % , P < 0.05 ) at week 3 and ( 5.84 0.75 ) mmol/L ( -5.81 % , P < 0.05 ) at week 6 in placebo group .